Deal Watch: Sandoz Licenses Posimir For Pain As Durect Generates Data For Resubmission
Executive Summary
Sandoz acquires rights to extended-release bupivacaine once held by Nycomed and Hospira in deal paying Durect $20m up front. Video interview: Partners Elasmogen and Feldan collaborate with Amgen.
You may also be interested in...
Durect's Posimir: NDA Resubmission Raises Similar Safety Issues
How to score adverse events for Durect's surgical pain treatment could determine whether US FDA advisory committee recommends bupivacaine extended-release solution; agency questions whether Posimir's formulation may cause neurological adverse events.
Keeping Track: US FDA Closes Out First Half Of 2019 With CRL For Edsivo, But A Burst Of Supplemental Approvals
The latest drug development news and highlights from our US FDA Performance Tracker.
Regeneron And Bluebird Team Up In Cell Therapy "Joint Venture"-Style Deal
Regeneron will make a $100m equity investment in bluebird to collaborate on the discovery of antibodies and T cell receptors, with the hope of building out in immuno-oncology and overcoming some of the early cell therapy challenges. Regeneron's business development chief talks to Scrip about its strategy.
Need a specific report? 1000+ reports available
Buy Reports